12Sep/13

Gilead leaps ahead with FDA app for PI3K cancer killer – FierceBiotech

Monoclonal Anti-CD20 Antibodies

Gilead leaps ahead with FDA app for PI3K cancer killer
FierceBiotech
As the biotech giant had said was a possibility, Gilead is seeking an early approval for idelalisib to combat indolent cases of non-Hodgkin’s lymphoma (NHL) that fail to respond to rituximab and alkylating-agent chemotherapies. Foster City, CA-based …
Gilead Seeks FDA Approval for IdelalisibYahoo! News
Idelalisib NDA Submitted for Indolent Non-Hodgkin’s LymphomaMonthly Prescribing Reference
Gilead Submits NDA for IdelalisibDrug Discovery & Development
PharmaTimes
all 8 news articles »
11Sep/13

Reports from Red Cross Hospital Highlight Recent Findings in Lymphoma – HispanicBusiness.com

Monoclonal Anti-CD20 Antibodies

Reports from Red Cross Hospital Highlight Recent Findings in Lymphoma
HispanicBusiness.com
According to news reporting originating in Shizuoka, Japan , by NewsRx journalists, research stated, “We retrospectively investigated high-dose chemotherapy (HDT) plus rituximab followed by autologous stem cell transplantation (ASCT) for patients with …
11Sep/13

« Mêmes chances » campaign : Quebeckers ask the Minister of Health and … – Canada NewsWire (press release)

Monoclonal Anti-CD20 Antibodies

« Mêmes chances » campaign : Quebeckers ask the Minister of Health and …
Canada NewsWire (press release)
Remember that this treatment, in combination with rituximab, is accessible to the majority of other Canadian provinces and prolongs survival without disease progression for patients with indolent non-Hodgkin Lymphoma (iNHL) from 31.2 months to 69.5 …
06Sep/13

Pixantrone-based regimen associated with lower cardiotoxicity in patients with … – Healio

Monoclonal Anti-CD20 Antibodies

Pixantrone-based regimen associated with lower cardiotoxicity in patients with …
Healio
… and colleagues conducted the investigation to compare the safety and efficacy of R-CHOP chemotherapy — cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (Rituxan; Genentech, Idec Pharmaceuticals) — with R-CPOP, substituting …
26Aug/13

Powerful new option for treating vasculitis – News-Medical.net

Monoclonal Anti-CD20 Antibodies

Powerful new option for treating vasculitis
News-Medical.net
Among patients receiving rituximab, 64 percent were in remission at six months, 48 percent at one year and 39 percent at 18 months, compared to 53 percent, 39 percent and 33 percent for standard therapy. “The FDA approved rituximab for vasculitis based …
UAB Part of Study of New Drug for VasculitisNewswise (press release)

all 2 news articles »